162 related articles for article (PubMed ID: 12227645)
1. Study on a novel strategy to treatment of phenylketonuria.
Liu J; Jia X; Zhang J; Xiang H; Hu W; Zhou Y
Artif Cells Blood Substit Immobil Biotechnol; 2002 Jul; 30(4):243-57. PubMed ID: 12227645
[TBL] [Abstract][Full Text] [Related]
2. [A new strategy of gene therapy for hyperphenylalaninemia rats].
Jia X; Liu J; Xiang H
Zhonghua Yi Xue Za Zhi; 2000 Jun; 80(6):464-7. PubMed ID: 11798804
[TBL] [Abstract][Full Text] [Related]
3. [Expression in Lactococcus lactis of catalytically active phenylalanine ammonia-lyase from parsley].
Xiang H; Liu J; Hu W; Zhu J; Zhu Z
Wei Sheng Wu Xue Bao; 1999 Jun; 39(3):196-204. PubMed ID: 12555534
[TBL] [Abstract][Full Text] [Related]
4. [The progressive study on gene therapy for hyperphenylalaninemia rats].
Zhang J; Liu JZ; Tan SZ; Jia XY; Zhou Y
Sheng Wu Gong Cheng Xue Bao; 2002 Nov; 18(6):713-7. PubMed ID: 12674642
[TBL] [Abstract][Full Text] [Related]
5. Phenylalanine ammonia-lyase modified with polyethylene glycol: potential therapeutic agent for phenylketonuria.
Ikeda K; Schiltz E; Fujii T; Takahashi M; Mitsui K; Kodera Y; Matsushima A; Inada Y; Schulz GE; Nishimura H
Amino Acids; 2005 Nov; 29(3):283-7. PubMed ID: 15977040
[TBL] [Abstract][Full Text] [Related]
6. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase.
Sarkissian CN; Shao Z; Blain F; Peevers R; Su H; Heft R; Chang TM; Scriver CR
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2339-44. PubMed ID: 10051643
[TBL] [Abstract][Full Text] [Related]
7. Blood phenylalanine reduction reverses gene expression changes observed in a mouse model of phenylketonuria.
Manek R; Zhang YV; Berthelette P; Hossain M; Cornell CS; Gans J; Anarat-Cappillino G; Geller S; Jackson R; Yu D; Singh K; Ryan S; Bangari DS; Xu EY; Kyostio-Moore SRM
Sci Rep; 2021 Nov; 11(1):22886. PubMed ID: 34819582
[TBL] [Abstract][Full Text] [Related]
8. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?
Sarkissian CN; Gámez A
Mol Genet Metab; 2005 Dec; 86 Suppl 1():S22-6. PubMed ID: 16165390
[TBL] [Abstract][Full Text] [Related]
9. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
[TBL] [Abstract][Full Text] [Related]
10. Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria.
Bell SM; Wendt DJ; Zhang Y; Taylor TW; Long S; Tsuruda L; Zhao B; Laipis P; Fitzpatrick PA
PLoS One; 2017; 12(3):e0173269. PubMed ID: 28282402
[TBL] [Abstract][Full Text] [Related]
11. Phenylalanine ammonia lyase (PAL): From discovery to enzyme substitution therapy for phenylketonuria.
Levy HL; Sarkissian CN; Scriver CR
Mol Genet Metab; 2018 Aug; 124(4):223-229. PubMed ID: 29941359
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.
Sarkissian CN; Kang TS; Gámez A; Scriver CR; Stevens RC
Mol Genet Metab; 2011 Nov; 104(3):249-54. PubMed ID: 21803624
[TBL] [Abstract][Full Text] [Related]
13. [High-level expression of phenylalanine ammonia-lyase in Lactococcus Lactis via synthesized sequence based on bias codons].
Chen X; Gao B; Jia XY; Su C; Lü YP; Wang ZY; Fan XP; Xiao B; Liu JZ
Sheng Wu Gong Cheng Xue Bao; 2006 Mar; 22(2):187-90. PubMed ID: 16607941
[TBL] [Abstract][Full Text] [Related]
14. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N
Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451
[TBL] [Abstract][Full Text] [Related]
15. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.
Burton BK; Longo N; Vockley J; Grange DK; Harding CO; Decker C; Li M; Lau K; Rosen O; Larimore K; Thomas J;
Mol Genet Metab; 2020 Aug; 130(4):239-246. PubMed ID: 32593547
[TBL] [Abstract][Full Text] [Related]
16. Biochemical analysis of Centaurea depressa phenylalanine ammonia lyase (PAL) for biotechnological applications in phenylketonuria (PKU).
Babaoğlu Aydaş S; Şirin S; Aslim B
Pharm Biol; 2016 Dec; 54(12):2838-2844. PubMed ID: 27246528
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report.
Safos S; Chang TM
Artif Cells Blood Substit Immobil Biotechnol; 1995; 23(6):681-92. PubMed ID: 8556141
[TBL] [Abstract][Full Text] [Related]
18. Partial rescue of neuropathology in the murine model of PKU following administration of recombinant phenylalanine ammonia lyase (pegvaliase).
Goldfinger M; Zeile WL; Corado CR; O'Neill CA; Tsuruda LS; Laipis PJ; Cooper JD
Mol Genet Metab; 2017 Sep; 122(1-2):33-35. PubMed ID: 28506393
[TBL] [Abstract][Full Text] [Related]
19. Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria.
Wang L; Gamez A; Sarkissian CN; Straub M; Patch MG; Han GW; Striepeke S; Fitzpatrick P; Scriver CR; Stevens RC
Mol Genet Metab; 2005; 86(1-2):134-40. PubMed ID: 16006165
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
Longo N; Zori R; Wasserstein MP; Vockley J; Burton BK; Decker C; Li M; Lau K; Jiang J; Larimore K; Thomas JA
Orphanet J Rare Dis; 2018 Jul; 13(1):108. PubMed ID: 29973227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
